Urology bills like three specialties stapled together. There is the office visit with a cystoscope in the next room, the procedure suite with its own global periods, and an ancillary business that includes a lab, imaging, and sometimes a radiation unit or a surgery center. Each one has its own way of getting denied. The most common leak is modifier 25 on an E/M that shares a day with a cystoscopy, a bladder instillation, or a catheter change. Payers audit it hard, and in-house staff either stick it on everything or stop using it after the first round of recoupments.
Then there is the global period mess. Ureteroscopy, lithotripsy, and prostate procedures carry global periods that swallow the follow-up visits, and a biller who does not track them will either miss the 58 and 78 modifiers or bill visits that should have been bundled. Prostate biopsy adds its own pile: MRI fusion, pathology that you may or may not be allowed to bill in-house, and prior authorization rules that change by plan. Drug billing is the other trap. Leuprolide for prostate cancer, Botox for overactive bladder, and BCG for bladder cancer are buy-and-bill, so units, wastage, and NDC details decide whether you get paid or carry the drug cost yourself. Medicare Advantage plans make prior auth worse, since each one keeps its own list.
Outsourcing makes sense for a urology group when the in-office lab, the infusion or instillation work, or a second location has outgrown one billing manager. It makes less sense if your real problem is a clinical documentation habit that starts at the exam room. A good urology biller reads operative notes, knows which procedures need a laterality or a stent modifier, and calls on aged AR instead of waiting for the next remit. In the request form, list your procedures, if you run a lab or a surgery center, your payer mix, and what your denial rate looks like right now. Billers can only quote what they can see.
